Literature DB >> 2497719

Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.

S C Hunt1, L L Wu, P N Hopkins, B M Stults, H Kuida, M E Ramirez, J M Lalouel, R R Williams.   

Abstract

Familial dyslipidemic hypertension (FDH) is a syndrome recently described from sibships selected for early familial hypertension and found to have one or more of three fasting lipid abnormalities [high triglycerides, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol]. In further analyses of these same 131 hypertensive subjects, apolipoprotein A-I and B, fasting plasma insulin (adjusted for body mass index), and detailed anthropometrics were different in two subgroups of FDH. Of 63 FDH patients, 19 met the criteria for familial combined hyperlipidemia (FCHL); 44 did not, but still had high triglyceride and/or low HDL cholesterol levels. When compared to 20 normolipidemic hypertensive patients, the 19 hypertensive patients with FCHL had 196% higher very low density lipoprotein cholesterol (p = 0.0001), 33% higher apolipoprotein B (p = 0.0002), smaller LDL particles (p = 0.007), and 73% higher fasting insulin (p = 0.003), but no significant differences in body mass index or skinfold thicknesses. The other 44 FDH patients without FCHL had 33% lower HDL (p = 0.0001), with only 8% lower apolipoprotein A-I levels (p = 0.20); significantly higher subscapular skinfolds (p = 0.02), weights (p = 0.002), body mass index (p = 0.006), knee widths (p = 0.0007), and wrist circumferences (p = 0.0009); smaller, denser LDL subfractions (p = 0.001); and increased apolipoprotein B levels (p = 0.01) compared to the normolipidemic hypertensive group. Increased fasting insulin levels were similar to the normolipidemic group and significantly lower than the FCHL group after adjustment for body mass index, suggesting a relationship between obesity and fasting insulin levels only in the non-FCHL group. We conclude that FDH consists of at least two subgroups: 1) FCHL with high apolipoprotein B, small LDL particles, and increased fasting plasma insulin levels, and 2) a less well-defined residual having upper central obesity with low HDL cholesterol and high triglyceride levels. Elevated insulin levels found in both groups, but possibly originating through different physiological mechanisms, may provide the pathophysiological connections between dyslipidemia, obesity, and hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2497719     DOI: 10.1161/01.atv.9.3.335

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  13 in total

1.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

2.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 3.  Insulin resistance and hypertension--implications for treatment.

Authors:  P A Rutherford; T H Thomas; R Wilkinson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

4.  Hypercholesterolemia and Dyslipidemia: Issues for the Clinician.

Authors:  H. Robert Superko; Nicolas A. Chronos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-02

5.  Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments?

Authors:  D Carmelli; L R Cardon; R Fabsitz
Journal:  Am J Hum Genet       Date:  1994-09       Impact factor: 11.025

Review 6.  The genetics of obesity and the metabolic syndrome.

Authors:  Keri L Monda; Kari E North; Steven C Hunt; D C Rao; Michael A Province; Aldi T Kraja
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

7.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

Authors:  E Ferrannini; S M Haffner; B D Mitchell; M P Stern
Journal:  Diabetologia       Date:  1991-06       Impact factor: 10.122

9.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

Authors:  S H Juo; S J Bredie; L A Kiemeney; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

10.  A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

Authors:  S M Haffner; L Mykkänen; D Robbins; R Valdez; H Miettinen; B V Howard; M P Stern; R Bowsher
Journal:  Diabetologia       Date:  1995-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.